2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

2:30PM-4:00PM: Abstract Number: 1833

Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease by Use of Mycophenolate at Baseline: Subgroup Analysis of the SENSCIS Trial

4M097: Systemic Sclerosis & Related Disorder – Clinical II: Cardiopulmonary Involvement (1830–1835)

2:30PM-4:00PM: Abstract Number: 1778

Entheseal CD90+ SOX9+ Cartilage-like Cells Initiate Spinal Ankylosis in Ankylosing Spondylitis

4M095: Spondyloarthritis Including Psoriatic Arthritis – Basic Science (1776–1781)

2:30PM-4:00PM: Abstract Number: 1770

Experimental Rheumatoid Joint Ameliorated by CRISPR Interference Targeting Long Non-coding RNA H19 Through Wnt Signaling Inactivation

4M093: RA – Animal Models (1770–1775)

2:30PM-4:00PM: Abstract Number: 1835

Frequency and Predictors of Meaningful Decline in Forced Vital Capacity During Follow up оf a Large Cohort of Systemic Sclerosis Associated Pulmonary Fibrosis Patients

4M097: Systemic Sclerosis & Related Disorder – Clinical II: Cardiopulmonary Involvement (1830–1835)

2:30PM-4:00PM: Abstract Number: 1766

GM-CSF Is a Pro-Inflammatory Cytokine in Experimental Vasculitis of Medium and Large Arteries

4M088: Cytokines & Cell Trafficking (1764–1769)

2:30PM-4:00PM: Abstract Number: 1796

Identifying Educational Themes and Knowledge Gaps Through Analysis of Electronic Consultation (eConsult) Communication Between Primary Care Physicians and Rheumatologists

4M089: Education (1794–1799)

2:30PM-4:00PM: Abstract Number: 1808

Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Persists After Immunotherapy Cessation

4M091: Miscellaneous Rheumatic & Inflammatory Disease II: Checkpoint Inhibitors-Induced & Other Rheumatic Conditions (1806–1811)

2:30PM-4:00PM: Abstract Number: 1806

Inflammatory Arthritis Induced by Immune Checkpoint Inhibitor Therapy: A Distinct Clinical Entity and Immunologic Phenotype

4M091: Miscellaneous Rheumatic & Inflammatory Disease II: Checkpoint Inhibitors-Induced & Other Rheumatic Conditions (1806–1811)

2:30PM-4:00PM: Abstract Number: 1765

Interferon-gamma Supports Transcriptional Activity of BIRC5 in CD4+ T Cells in Established Rheumatoid Arthritis

4M088: Cytokines & Cell Trafficking (1764–1769)

2:30PM-4:00PM: Abstract Number: 1814

Long-term Outcome of Juvenile Idiopathic Arthritis: From the Methotrexate to the Biologic Era

4M092: Pediatric Rheumatology – Clinical II: JIA (1812–1817)

2:30PM-4:00PM: Abstract Number: 1823

Magnetic Resonance Enterography as a Screening Tool to Detect Sacroiliitis in Crohn’s Disease: Association with Clinical and Endoscopic Markers of Crohn’s Disease Activity

4M096: Spondyloarthritis Including Psoriatic Arthritis – Clinical III: Miscellaneous (1818–1823)

2:30PM-4:00PM: Abstract Number: 1780

Microbiome in Offspring of Ankylosing Spondylitis Patients

4M095: Spondyloarthritis Including Psoriatic Arthritis – Basic Science (1776–1781)

2:30PM-4:00PM: Abstract Number: 1771

MyD88 S209R Enhances Inflammation in Mouse Models of Arthritis

4M093: RA – Animal Models (1770–1775)

2:30PM-4:00PM: Abstract Number: 1769

Myosin Regulation of TNF Receptor 2 Signaling May Contribute to Anti-TNF Therapy Response

4M088: Cytokines & Cell Trafficking (1764–1769)

2:30PM-4:00PM: Abstract Number: 1813

New Medications Are Needed for Children with Juvenile Idiopathic Arthritis

4M092: Pediatric Rheumatology – Clinical II: JIA (1812–1817)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].